What is the price of zomedica stock now?
Feb 17, 2022 · Why Zomedica Stock Soared 72.4% This Week. By Jim Halley - Feb 17, 2022 at 5:52PM Key Points. The company reported only $22,514 in revenue in the third quarter. Zomedica was the 25th most traded ...
Is Zom stock a good buy right now?
Apr 15, 2022 · Zomedica's stock was trading at $0.2078 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZOM shares have increased by 51.1% and is now trading at $0.3140. View which stocks have been most impacted by COVID-19.
Will zomedica stock outperform or underperform the S&P 500 over the long term?
Mar 06, 2021 · In the meantime, it could be the perfect time to pick up some Zomedica stock to make sure that you benefit from its growth potential. …
Where is zomedica based?
Feb 05, 2021 · What happenedShares of Zomedica (NYSEMKT: ZOM) hit a new 52-week high on Friday. As of 12:25 p.m. EST, the veterinary health company's stock price was up more than 24%.
Is Zomedica stock expected to go up?
Stock Price Forecast The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +319.14% increase from the last price of 0.29.
Is Zomedica a good stock to buy?
In the final analysis, ZOM stock is highly risky and best suited for speculative traders. Yet it's possible that retail traders will bid the stock up in 2022. And if they abandon Zomedica, it would be a dog-gone shame.Jan 7, 2022
Why is ZOM stock climbing?
Shares of Zomedica ( ZOM -5.49% ) climbed on Friday after the animal health specialist struck a deal to acquire Pulse Veterinary Technologies. By the close of trading today, Zomedica's stock price was up 9.8% after rising as much as 21.2% earlier in the day.Oct 1, 2021
Is Zomedica overvalued?
Is Zomedica stock overvalued? Zomedica shares soared near the beginning of 2021, but then plummeted over 80% from their highest share price. In retrospect, it seems like shareholders had pie-in-the-sky dreams for Truforma, the company's point-of-care diagnostic system.
Why has Zomedica stock dropped?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.Nov 18, 2021
Could Zomedica be a millionaire maker?
The biggest reason Zomedica might not be a millionaire-maker stock is that the business has a long way to go in showing that it can generate strong sales numbers. And that's ultimately going to be tied to whether Truforma is successful or not.May 19, 2021
Is ZOM shorted?
Short Shares Availability This table shows the number of shares of US:ZOM available to be shorted at a leading prime brokerage. It is not the total number of shares available to short, nor is it the short interest.
Who invested in Zomedica?
Top 10 Owners of Zomedica CorpStockholderStakeShares bought / soldThe Vanguard Group, Inc.4.14%+181,358SSgA Funds Management, Inc.2.93%+5,932,371BlackRock Fund Advisors1.19%-5,530,082Cambridge Investment Research Adv...1.14%+8456 more rows
Is Zomedica undervalued?
InvestorPlace's Mark Hake estimates Zomedica (NYSEAMERICAN:ZOM) is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy at current prices.Jun 28, 2021
Will TXMD stock go up?
Given the current short-term trend, the stock is expected to rise 26.67% during the next 3 months and, with a 90% probability hold a price between $0.33 and $0.59 at the end of this 3-month period.
How has Zomedica's stock been impacted by COVID-19 (Coronavirus)?
Zomedica's stock was trading at $0.2078 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organ...
When is Zomedica's next earnings date?
Zomedica is scheduled to release its next quarterly earnings announcement on Tuesday, May 10th 2022. View our earnings forecast for Zomedica .
How were Zomedica's earnings last quarter?
Zomedica Corp. (NYSEAMERICAN:ZOM) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per shar...
What guidance has Zomedica issued on next quarter's earnings?
Zomedica issued an update on its FY 2021 earnings guidance on Monday, March, 14th. The company provided earnings per share (EPS) guidance of for th...
Who are Zomedica's key executives?
Zomedica's management team includes the following people: Mr. Robert Cohen , CEO & Director (Age 63, Pay $412.79k) Ms. Ann Marie Cotter CPA , C...
Who are some of Zomedica's key competitors?
Some companies that are related to Zomedica include Protagonist Therapeutics (PTGX) , Keros Therapeutics (KROS) , Myovant Sciences (MYOV) , Axs...
What is Zomedica's stock symbol?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
Who are Zomedica's major shareholders?
Zomedica's stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (2.93%), BlackR...
Which institutional investors are selling Zomedica stock?
ZOM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Commonwealt...
About Zomedica
Zomedica (NYSEAMERICAN:ZOM) Frequently Asked Questions
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs.
When will Zomedica be available for dogs?
Zomedica's stock was trading at $0.2078 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZOM stock has increased by 63.8% and is now trading at $0.3403. View which stocks have been most impacted by COVID-19.
When did Alex start writing for the Fool?
The biggest reason why people are talking about Zomedica right now is that Truforma is scheduled to launch on March 30. At launch, it'll be capable of five different diagnostic assays for cats and dogs. Two more assays will be out the door by the end of 2021.
Who is the CEO of Zomedica?
Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur.
Signals & Forecast
Zomedica's ascent began in January of this year, when it announced the arrival of a new CEO, Robert Cohen. Shortly thereafter, Reddit traders piled into the stock, causing it to grow explosively and putting it on the map for the first time.
Support, Risk & Stop-loss
The Zomedica Pharmaceuticals Corp stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Is Zomedica Pharmaceuticals Corp stock A Buy?
Zomedica Pharmaceuticals Corp finds support from accumulated volume at $0.36 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Zomedica Pharmaceuticals Corp
Zomedica Pharmaceuticals Corp holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Golden Star Signal
In the last 100 trades there were 77.16 million shares bought and 11.3 million shares sold. The last trade was done 97 days ago by Powers Johnny D who bough 250 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
What is the global companion animal diagnostics market?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
How much is net cash used for 2020?
The companion animal diagnostics market is forecast to reach $2.8 billion by 2024, at a compounded annual growth rate (CAGR) of 9.8% from 2019 to 2024. In addition, the global veterinary immunodiagnostic market has been predicted to expand at a CAGR of 9.6% and reach $2.1 billion by the year 2022.
How much is General and Administrative expense for 2020?
Net cash from investing activities for the year ended December 31, 2020 was approximately $1.0 million, compared to net cash used of approximately $0.7 million for the year ended December 31, 2019, an increase of approximately $1.7 million, or 246%.
How much will the pet diagnostics market be in 2024?
General and administrative expense for the year ended December 31, 2020 was approximately $6.0 million, compared to approximately $7.0 million for the year ended December 31, 2019, a decrease of approximately $1.0 million or 15%.
Is Zomedica in the development stage?
consumers were expected to have spent $99 billion on their pets in 2020. The companion animal diagnostics market is forecast to reach $2.8 billion by 2024, at a compounded annual growth rate (CAGR) of 9.8% from 2019 to 2024.
How many direct sales representatives will ZOM hire in 2021?
Zomedica, which is in the development stage, recorded no revenues in 2020. The 2020 net loss resulted from research and development (“R&D”) expenses of approximately $8.0 million, general and administrative (“G&A”) expenses of approximately $6.0 million, and professional fees of approximately $2.2 million.
When will Zom's Truforma be available?
ZOM plans to hire fifteen direct sales representatives by the end of 2021, as well as four veterinarians who will perform professional services, as well as inside sales representatives and customer service personnel.
Where is Zomedica located?
It is also expected that ZOM’s TRUFORMA will be available in select markets outside the United States in 2022.
How much will Zomedica make in 2022?
Zomedica is a veterinary health company based in Ann Arbor , Michigan, that focuses on meeting the unmet needs of clinical veterinarians. ZOM intends to offer a product portfolio that emphasizes both patient and practitioner health by developing innovative diagnostics and medical devices.
What is Truforma used for?
From a valuation perspective, analysts expect Zomedica to post revenues of $15.21 million in 2022, which would mean a 2022 price-to-sales multiple of over 62x. That said, ZOM shouldn't be valued on near-term earnings but long-term potential as its revenues would increase significantly after Truforma has commercial success.
Is Zom stock a good investment?
Truforma is a point-of-care device meant to be used by veterinary doctors. The platform would help detect thyroid and adrenal diseases in pets. Add the projected growth in pet care in the U.S. and we had a fundamental story around Zomedica. Article continues below advertisement.
Is Zom a penny stock?
ZOM stock is a good long-term investment. ZOM looks like a good long-term investment. In its filing, citing data from MarketsandMarkets, ZOM said that the market opportunity for companion animal diagnostics is expected to rise from $1.7 billion in 2019 to $2.8 billion in 2024. Article continues below advertisement.
Can short squeezes trigger short term price movement?
Since ZOM is a penny stock, not many analysts are covering the stock. According to the estimates compiled by CNN Business, only one analyst is covering ZOM stock. The analyst has assigned a $1.2 target price, which is a premium of around 20 percent over the current prices.
Is Truforma a recurring revenue?
Usually, short squeezes can only trigger a short-term price movement. However, as we’ve seen this year, the short squeeze can also have a medium to long-term impact. Many of the companies that were pumped by WallStreetBets capitalized on the rise in their stocks to issue more shares. ZOM also issued more shares, ...
